PARIS & CAMBRIDGE, Mass.--
a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Alnylam
Pharmaceuticals, Inc. (NASDAQ: ALNY) announced today that they have
significantly expanded their strategic agreement to develop and
commercialize treatments for rare genetic diseases. Genzyme will have
significant rights to Alnylam’s portfolio of clinical and pre-clinical
stage drug candidates.more...